论文部分内容阅读
目的美多巴联合帕宁方治疗帕金森病的临床疗效观察。方法选取我院2011年2月至2012年6月32例帕金森病患者,随机分成两组,对照组16例仅给予美多巴治疗,治疗组16例进行美多巴联合帕宁方进行治疗,疗程均为12周。观察两组临床疗效、改良Webster评分及不良反应。结果治疗后治疗组的Webster评分明显低于对照组,差异有统计学意义(P<0.05),治疗组16例帕金森病患者中特别显效4例,显效6例,有效3例,无效3例,总有效率(81.25%)高于对照组,差异有统计学意义(56.25%,P<0.05),治疗组1例出现恶心,无其他不良反应。结论美多巴联合帕宁方治疗帕金森病患者,疗效显著,值得推广。
Objective To observe the curative effect of metopar combined with paeonfang in the treatment of Parkinson’s disease. Methods 32 patients with Parkinson’s disease in our hospital from February 2011 to June 2012 were randomly divided into two groups, 16 patients in the control group were treated with metoprolol only, and 16 patients in the treatment group were treated with Palindang , Treatment for 12 weeks. The clinical efficacy, modified Webster score and adverse reactions were observed. Results After treatment, the Webster score of the treatment group was significantly lower than that of the control group (P <0.05). In the treatment group, 16 patients with Parkinson’s disease were especially markedly effective in 4 cases, markedly effective in 6 cases, effective in 3 cases and ineffective in 3 cases , The total effective rate (81.25%) was higher than the control group, the difference was statistically significant (56.25%, P <0.05). One patient in the treatment group had nausea and no other adverse reactions. Conclusion Combined treatment of Parkinson and Palpaton in patients with Parkinson’s disease, the effect is significant, it is worth promoting.